Ollin Biosciences Announces Oversubscribed $330M Series B Financing
Ollin Biosciences raised $330M in an oversubscribed Series B to advance global Phase 3 development of OLN324 in DME and wet AMD, studies commencing in second half of 2026.
Ollin Biosciences
Private
Ollin Biosciences is a clinical-stage ophthalmology company developing a next-generation anti-VEGF challenger to Regeneron's Eylea and Roche's Vabysmo for retinal disease. The company raised a $330M Series B in 2026 to fund pivotal Phase 3 trials of its lead asset.
Company Info
Sector:Biotechnology / Ophthalmology / Anti-VEGF
Headquarters:South San Francisco, California, USA
Founded:2020
Website:ollin.bio/
Clinical Development Pipeline
OLN-102
Target: Bispecific anti-VEGFRecent News
Leadership Team
Jason Ehrlich, M.D., Ph.D.
Co-Founder and Chief Executive Officer
Careers & Job Openings